Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904518 | 0.90 | CHEK2 (0.35) | PTGS2PTGS1CYP11B1CYP11B2RORC | |
| SCHEMBL15556599 | 0.79 | ENPP2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL17394519 | 0.79 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL17394481 | 0.78 | PTGS2 (0.39) | PTGS2PTGS1 | |
| SCHEMBL17394416 | 0.77 | PTGS2 (0.33) | PTGS2CYP11B1CYP11B2 | |
| SCHEMBL15904417 | 0.75 | PTGS2 (0.49) | PTGS2PTGS1CYP11B1CYP11B2 | |
| SCHEMBL16458709 | 0.72 | ROCK1 (0.35) | — | |
| SCHEMBL17394415 | 0.70 | DGAT1 (0.32) | — | |
| SCHEMBL16458878 | 0.69 | BACE1 (0.31) | — | |
| SCHEMBL11649861 | 0.69 | PTGS2 (0.52) | PTGS2PTGS1CYP11B1CYP11B2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948440-B1 | ANTIVIRAL TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9511059-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-10 | — | — | US | disclosed |
| EP-2948440-A1 | ANTIVIRAL TRIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014114573-A1 | ANTIVIRAL TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140242028-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PTGS2 2158/4885PTGS1 837/4885CYP11B1 797/4885 |
| US-20150353511-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | PTGS2 2158/4885PTGS1 837/4885CYP11B1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.